
Florence Namour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6354607/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clinical Pharmacokinetics, 2015, 54, 859-874.	3.5	112
2	Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAKâ€1 Inhibitor, After Shortâ€Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis and Rheumatology, 2017, 69, 1949-1959.	5.6	66
3	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. Drug Metabolism Letters, 2016, 10, 38-48.	0.8	49
4	Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. British Journal of Clinical Pharmacology, 2016, 82, 139-148.	2.4	46
5	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. British Journal of Clinical Pharmacology, 2018, 84, 2779-2789.	2.4	23
6	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Annals of the Rheumatic Diseases, 2013, 72, 741-744.	0.9	18
7	The Relative Bioavailability and Effects of Food and Acidâ€Reducing Agents on Filgotinib Tablets in Healthy Subjects. Clinical Pharmacology in Drug Development, 2019, 8, 585-594.	1.6	16
8	Filgotinib: A Clinical Pharmacology Review. Clinical Pharmacokinetics, 2022, 61, 819-832.	3.5	13
9	Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects. Drugs in R and D, 2012, 12, 141-163.	2.2	11
10	Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection― Clinical Pharmacokinetics, 2015, 54, 1297-1298.	3.5	7
11	Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects. Clinical Pharmacology in Drug Development, 2020, 9, 32-40.	1.6	7
12	Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition. Clinical Pharmacology and Therapeutics, 2022, 112, 901-908.	4.7	2